In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

Lilly/Boehringer Ingelheim's insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen. The marketing authorisation for the Alliance's insulin glargine ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...